Literature DB >> 21864296

Absence of ABCG2-mediated mucosal detoxification in patients with active inflammatory bowel disease is due to impeded protein folding.

J Jasper Deuring1, Colin de Haar, Chantal L Koelewijn, Ernst J Kuipers, Maikel P Peppelenbosch, C Janneke van der Woude.   

Abstract

Xenotoxic damage in inflammatory diseases, including IBD (inflammatory bowel disease), is compounded by reduced activity of the xenobiotic transporter ABCG2 (ATP-binding-cassette G2) during the inflammatory state. An association between the activation of the unfolded protein response pathway and inflammation prompted us to investigate the possibility that reduced ABCG2 activity is causally linked to this response. To this end, we correlated expression of ABCG2 and the unfolded protein response marker GRP78 (glucose-regulated protein of 78 kDa) in colon biopsies from healthy individuals (n=9) and patients with inactive (n=67) or active (n=55) IBD, ischaemic colitis (n=10) or infectious colitis (n=14). In addition, tissue specimens throughout the small bowel from healthy individuals (n=27) and from patients with inactive (n=9) or active (n=25) Crohn's disease were co-stained for ABCG2 and GRP78. In all biopsies from patients with active inflammation, irrespective of the underlying disease, an absolute negative correlation was observed between epithelial ABCG2 expression and GRP78 expression, suggesting that inflammation-dependent activation of the unfolded protein response is responsible for suppression of ABCG2 function. The link between the unfolded protein response and functional ABCG2 expression was further corroborated by live imaging of ABCG2-expressing cells, which showed that various inflammatory mediators, including nitric oxide, activate the unfolded protein response and concomitantly reduce plasma membrane localization as well as transport function of ABCG2. Thus a novel mechanism for explaining xenobiotic stress during inflammation emerges in which intestinal inflammation activates the unfolded protein response, in turn abrogating defences against xenobiotic challenge by impairing ABCG2 expression and function.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21864296     DOI: 10.1042/BJ20111281

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  13 in total

1.  Profiling of ABC transporters during active ulcerative colitis and in vitro effect of inflammatory modulators.

Authors:  Nirmal Verma; Vineet Ahuja; Jaishree Paul
Journal:  Dig Dis Sci       Date:  2013-03-20       Impact factor: 3.199

2.  Elderly-onset IBD: a milder disease?

Authors:  Christina Ha; Seymour Katz
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-04-02       Impact factor: 46.802

Review 3.  Role of endoplasmic reticulum stress and autophagy as interlinking pathways in the pathogenesis of inflammatory bowel disease.

Authors:  Shuhei Hosomi; Arthur Kaser; Richard S Blumberg
Journal:  Curr Opin Gastroenterol       Date:  2015-01       Impact factor: 3.287

4.  Citrobacter rodentium Infection Inhibits Colonic P-glycoprotein Expression.

Authors:  Mitul Patel; Anoop Kumar; Dulari Jayawardena; Shubha Priyamvada; Arivarasu N Anbazhagan; Waddah A Alrefai; Ravinder K Gill; Pradeep K Dudeja; Seema Saksena
Journal:  Gene Rep       Date:  2019-10-31

5.  Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.

Authors:  Vibeke Andersen; Katrine Svenningsen; Lina Almind Knudsen; Axel Kornerup Hansen; Uffe Holmskov; Allan Stensballe; Ulla Vogel
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

Review 6.  Regulation of colonic epithelial butyrate transport: Focus on colorectal cancer.

Authors:  Pedro Gonçalves; Fátima Martel
Journal:  Porto Biomed J       Date:  2016-07-01

7.  P-glycoprotein multidrug transporter in inflammatory bowel diseases: More questions than answers.

Authors:  Elke Cario
Journal:  World J Gastroenterol       Date:  2017-03-07       Impact factor: 5.742

8.  Low dose Naltrexone for induction of remission in inflammatory bowel disease patients.

Authors:  Mitchell R K L Lie; Janine van der Giessen; Gwenny M Fuhler; Alison de Lima; Maikel P Peppelenbosch; Cokkie van der Ent; C Janneke van der Woude
Journal:  J Transl Med       Date:  2018-03-09       Impact factor: 5.531

Review 9.  The unfolded protein response and gastrointestinal disease.

Authors:  Arthur Kaser; Timon Erik Adolph; Richard S Blumberg
Journal:  Semin Immunopathol       Date:  2013-04-16       Impact factor: 9.623

Review 10.  Cellular and Molecular Connections between Autophagy and Inflammation.

Authors:  Pierre Lapaquette; Jean Guzzo; Lionel Bretillon; Marie-Agnès Bringer
Journal:  Mediators Inflamm       Date:  2015-06-29       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.